These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 25170796)

  • 1. Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women.
    Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
    Urol Int; 2014; 93(4):470-3. PubMed ID: 25170796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron.
    Kosilov K; Loparev S; Ivanovskaya M; Kosilova L
    Arch Gerontol Geriatr; 2015; 61(2):212-6. PubMed ID: 26169181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients With Benign Prostatic Hyperplasia.
    Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
    Am J Mens Health; 2016 Mar; 10(2):157-63. PubMed ID: 26186951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods].
    Kosilov KV; Loparev SA; Krasnykh MA; Kosilova LV
    Adv Gerontol; 2014; 27(1):149-55. PubMed ID: 25051773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
    Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G;
    BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acupuncture versus solifenacin for treatment of overactive bladder and its correlation with urine nerve growth factor levels: a randomized, placebo-controlled clinical trial.
    Aydoğmuş Y; Sunay M; Arslan H; Aydın A; Adiloğlu AK; Şahin H
    Urol Int; 2014; 93(4):437-43. PubMed ID: 25033919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decrease of risk of developing symptoms of OAB in elderly men and women treated with loop diuretic for hypertensive disease using solifenacin.
    Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
    Curr Aging Sci; 2014; 7(3):229-34. PubMed ID: 25495568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome.
    Hsiao SM; Lin HH; Kuo HC
    Neurourol Urodyn; 2014 Mar; 33(3):331-4. PubMed ID: 23494586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [PROSPECTS FOR THE TREATMENT OF IDIOPATHIC AND NEUROGENIC OVERACTIVE BLADDER].
    Kamalov AA; Korshunova ES; Popov GR; Khodyreva LA; Dudareva AA; Nizov AN
    Urologiia; 2015; (1):30-2, 34-5. PubMed ID: 26094383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
    Zinner NR; Dmochowski RR; Staskin DR; Siami PF; Sand PK; Oefelein MG
    Neurourol Urodyn; 2011 Sep; 30(7):1214-9. PubMed ID: 21462240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of solifenacin in patients with overactive bladder syndrome.
    Oresković S; But I; Banović M; Goldstajn MS
    Coll Antropol; 2012 Mar; 36(1):243-8. PubMed ID: 22816227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined antimuscarinics for treatment of neurogenic overactive bladder.
    Nardulli R; Losavio E; Ranieri M; Fiore P; Megna G; Bellomo RG; Cristella G; Megna M
    Int J Immunopathol Pharmacol; 2012; 25(1 Suppl):35S-41S. PubMed ID: 22652160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride.
    Metello J; Nogueira B; Torgal M; Colaço J; Vieira A; Gonçalves V; Retto H
    Int Urogynecol J Pelvic Floor Dysfunct; 2007 Sep; 18(9):1021-5. PubMed ID: 17211528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of solifenacin vs. trospium in the treatment of patients with overactive bladder in the German National Health Service.
    Nazir J; Hart WM
    J Med Econ; 2014 Jun; 17(6):408-14. PubMed ID: 24720775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.